GlobeNewswire·Nov 10, 2026, 3:32 PM ET

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Genmab A/S will increase its share capital by 164,828 shares due to employee warrant exercises.
The capital increase has no preemption rights for existing shareholders & shares are subscribed in cash.
Shares are issued at varying prices ranging from DKK 1,362.5 to DKK 3,172 per share.
Total proceeds to the company are approximately DKK 369.7 million.
The increase represents approximately 0.2641% of the company's total share capital.
New shares are ordinary, freely transferable, & carry rights to dividends & other corporate rights from the subscription date.
New shares will be listed on Nasdaq Copenhagen following registration with the Danish Business Authority.
The total nominal value of share capital after the increase is DKK 62,570,683, corresponding to 62,570,683 votes.
Genmab is a biotechnology company headquartered in Copenhagen focused on antibody medicines for cancer & other serious diseases.